Congenital Bleeding Disorders and COVID-19—A Systematic Literature Review

 

 Buy Article Permissions and Reprints

Abstract

Hypercoagulability is a prominent feature of coronavirus disease 2019 (COVID-19) and can lead to fatal consequences. Although the impact of COVID-19 on several disorders is well-established, its effect on congenital bleeding disorders (CBDs) is not well-documented. To address this ambiguity, a systematic review was conducted on the available studies to determine the impact of COVID-19 and vaccination aimed to prevent COVID-19 on patients with CBDs. We performed a systematic literature review using relevant keywords and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. We conducted our search on the PubMed, Scopus, and Web of Science databases until July 2023. Out of 31 included studies, 12 case series covering 770 patients with CBD and COVID-19 were further analyzed. The majority of the patients had hemophilia A (n = 352, ∼46%) or hemophilia B (n = 74, ∼10%), while the remaining patients had von Willebrand disease (n = 43, 5.6%) or rare bleeding disorders (n = 27, 3.5%). A total of 25 deaths (3.2%) and 22 intensive care unit admissions (2.8%) were recorded. Bleeding complications were reported in the majority of the 12 case series (n = 7, 58.3%) and in most of the case reports (n = 8, ∼57%), while thrombotic complications were only reported in two studies (16.6%). The mortality rate ranged from 0% in five studies (41.6%) to 5.7% and the rate of hospitalization ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the thrombotic complication rate in one study was 6.9%. The mortality rate varied from 0 to 5.7%, and the hospitalization rate ranged from 0 to 40%. Bleeding complications were reported in a range of 0 to 81%, while the rate of thrombotic complications in one study was 6.9%. Vaccination was reported in five case series, which included 821 patients with CBDs with the majority having hemophilia A (n = 479; 67.2%) and hemophilia B (n = 85; ∼12%). The most frequently reported side effects were myalgia (6.5%), flu-like symptoms (4.8%), fever (4.7%), and headache (4%). COVID-19 in patients with CBDs appears to provoke thrombotic complications and bleeding events more frequently, as well as a higher rate of hospitalization, which may be partially due to the increased risk of bleeding events. Although it seems that patients with CBD have lower mortality rates, further studies are necessary to fully understand this, especially considering comorbidities and low number of available studies.

Publication History

Article published online:
27 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Pradhan M, Shah K, Alexander A. et al. COVID-19: clinical presentation and detection methods. J Immunoassay Immunochem 2022; 43 (01) 1951291
  CrossrefPubMedGoogle Scholar
• 2 Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev 2021; 37 (02) e3377
  CrossrefPubMedGoogle Scholar
• 3 Spyropoulos AC, Levy JH, Ageno W. et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18 (08) 1859-1865
  CrossrefPubMedGoogle Scholar
• 4 Schulman S, Sholzberg M, Spyropoulos AC. et al; International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemost 2022; 20 (10) 2214-2225
  CrossrefPubMedGoogle Scholar
• 5 Dorgalaleh A, Tabibian S, Baghaipour MR. et al. Challenges and concerns of patients with congenital bleeding disorders affected by coronavirus disease 2019. Blood Coagul Fibrinolysis 2021; 32 (03) 200-203
  CrossrefPubMedGoogle Scholar
• 6 Zülfikar HKB, Gözüdok G, Züfikar B. Medical and socio-psychological consequences of the COVID-19 pandemic on people with congenital bleeding disorders and their caregivers. CJN 2023; 2: 1-6
  PubMedGoogle Scholar
• 7 Dorgalaleh A, Dabbagh A, Tabibian S. et al. Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)?. Semin Thromb Hemost 2020; 46 (07) 853-855
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Álvarez Román MT, Butta Coll N, García Barcenilla S. et al. Registry of patients with congenital bleeding disorders and COVID-19 in Madrid. Haemophilia 2020; 26 (05) 773-778
  CrossrefPubMedGoogle Scholar
• 9 Zaki N, Alashwal H, Ibrahim S. Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review. Diabetes Metab Syndr 2020; 14 (05) 1133-1142
  CrossrefPubMedGoogle Scholar
• 10 Barh D, Tiwari S, Andrade BS. et al. A novel multi-omics-based identification of symptoms, comorbid conditions, and possible long-term complications in COVID-19. Mol Omics 2021; 17 (02) 317-337
  CrossrefPubMedGoogle Scholar
• 11 Spiezia L, Boscolo A, Poletto F. et al. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost 2020; 120 (06) 998-1000
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Dorgalaleh A, Tabibian S, Mohammadamini M. et al. Do congenital bleeding disorders have a protective effect against COVID-19? A prospective study. Int J Lab Hematol 2021; 43 (03) e124-e127
  CrossrefPubMedGoogle Scholar
• 13 Coluccia A, Marchesini E, Giuffrida AC. et al; AICE MECCOVID-19 Study Group. Addressing the impact of SARS-CoV-2 infection in persons with congenital bleeding disorders: the Italian MECCOVID-19 study. Haemophilia 2021; 27 (04) e575-e578
  CrossrefPubMedGoogle Scholar
• 14 Sharathkumar A, Wendt L, Ortman C. et al; National COVID Cohort Collaborative Consortium. COVID-19 outcomes in persons with hemophilia: results from a US-based national COVID-19 surveillance registry. J Thromb Haemost 2024; 22 (01) 61-75
  CrossrefPubMedGoogle Scholar
• 15 Koc B, Zulfikar B. COVID-19 experience with inherited bleeding disorders similar to the country population. Haemophilia 2022; 28: 32
  PubMedGoogle Scholar
• 16 Gökçebay DG, Şenol BK, Kurtipek FB, Çulha VK, Özbek NY, Zülfikar B. The effects of coronavirus disease 2019 pandemic on patients with hemophilia and inherited bleeding disorders: results from 2 centers in Turkey. Age (years, mean ± SD). Turk Pediatri Ars 2023; 28: 14
  PubMedGoogle Scholar
• 17 Perdomo-Amar I, Orozco-Gonzalez C, Duque-Ortega J. et al. Characterization of inherited coagulation disorders patients and COVID-19 infection in COLOMBIA. Haemophilia 2021; 27: 51-52
  PubMedGoogle Scholar
• 18 Ferroudj N, Bensadok M, Daikhi F, Chennoukh K, Zidani N, Nekkal S. Patients with congenital bleeding disorders and COVID-19: from one center in Algiers, Algeria. Haemophilia 2021; 27: 161
  PubMedGoogle Scholar
• 19 Hermans C, Astermark J, Carvalho M. et al. Prevalence of COVID-19 related hospitalizations and mortality in adults aged ≥40 years with haemophilia: a survey from Europe. Haemophilia 2023; 29 (03) 913-916
  CrossrefPubMedGoogle Scholar
• 20 Sikorska A, Stefanska-Windyga E, Windyga J. Clinical course of COVID-19 in patients with inherited bleeding disorders: an interim analysis of 28 cases [abstract]. Res Pract Thromb Haemost. 2021 ; 5 (Suppl 2). Accessed July 14, 2023 at: https://abstracts.isth.org/abstract/clinical-course-of-covid-19-in-patients-with-inherited-bleeding-disorders-an-interim-analysis-of-28-cases/
  PubMedGoogle Scholar
• 21 Yakovleva EV, Vybornykh DE, Gemdzhian EG, Zozulya NI. COVID-19 in patients with congenital bleeding disorders in Russia. Gematol Transfuziol 2023; 68 (02) 219-228
  CrossrefPubMedGoogle Scholar
• 22 Yousefi M, Sinaei R, Zadeh AS, Farrokhnia M, Dalfardi B. Short-time safety of the Sinopharm COVID-19 vaccine in patients with hemophilia. Arch Clin Infect Dis 2021;16(06):
  PubMedGoogle Scholar
• 23 Karimi MSA, Haghpanah S, Zarei T, Bazrafshan A. Safety of Sinopharm covid-19 vaccine in Iranian patients with congenital bleeding disorders: a preliminary report [abstract]. ISTH; 2022 . Accessed July 14, 2023 at: https://abstracts.isth.org/abstract/safety-of-sinopharm-covid-19-vaccine-in-iranian-patients-with-congenital-bleeding-disorders-a-preliminary-report/
  PubMedGoogle Scholar
• 24 Arrieta V, Williams M, Mendez A, Simonella M, Bordone R. Development of factor inhibitors in congenital haemophilia patients after following COVID-19 vaccination. A Health Center experience. Haemophilia 2022; 28: 40
  PubMedGoogle Scholar
• 25 Atay MH, Kelkıtlı E. The practice of COVID-19 vaccination in patients bleeding disorders. J Exp Clin Med 2022; 39 (03) 767-769
  CrossrefPubMedGoogle Scholar
• 26 Tiede A, Leise H, Horneff S. et al. Safety of intramuscular COVID-19 vaccination in patients with haemophilia. Haemophilia 2022; 28 (05) 687-693
  CrossrefPubMedGoogle Scholar
• 27 Babaee E, Amirkafi A, Tehrani-Banihashemi A. et al. Adverse effects following COVID-19 vaccination in Iran. BMC Infect Dis 2022; 22 (01) 476
  CrossrefPubMedGoogle Scholar
• 28 Al Khames Aga QA, Alkhaffaf WH, Hatem TH. et al. Safety of COVID-19 vaccines. J Med Virol 2021; 93 (12) 6588-6594
  CrossrefPubMedGoogle Scholar
• 29 Dorgalaleh A, Narouei F, Asadi M, Khamsi HM, Gholami MS. Congenital bleeding disorders and COVID-19 - an emphasis on the role of thrombosis as one of the main causes of morbidity and mortality in COVID-19. Cardiovasc Hematol Disord Drug Targets 2022; 22 (02) 83-86
  CrossrefPubMedGoogle Scholar
• 30 Coronavirus COVID-19 Global Cases. Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Accessed September 5, 2023 at: www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
  PubMedGoogle Scholar
• 31 Coronavirus Age. Sex, demographics (COVID-19). Worldometer. Accessed September 5, 2023 at: https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/
  PubMedGoogle Scholar
• 32 WHO. The true death toll of COVID-19: Estimating global excess mortality. Accessed September 15, 2023 at: https://www.who.int/data/stories/the-true-death-toll-of-covid-19-estimating-global-excess-mortality
  PubMedGoogle Scholar
• 33 Coronavirus Age, Sex, Demographics (COVID-19) – Worldometer. . Accessed September 15, 2023 at: https://www.worldometers.info/coronavirus/coronavirus-age-sex-demographics/
  PubMedGoogle Scholar
• 34 Girolami A, Tezza F, Scapin M, Vettore S, Casonato A. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis 2006; 21 (02) 175-178
  CrossrefPubMedGoogle Scholar
• 35 Dorgalaleh A, Baghaipour MR, Tabibian S. et al. Gastrointestinal bleeding in a newborn infant with congenital factor X deficiency and COVID-19-A common clinical feature between a rare disorder and a new, common infection. Int J Lab Hematol 2020; 42 (06) e277-e279
  CrossrefPubMedGoogle Scholar
• 36 Quintavalle G, Coppola A, Ruggieri A. et al. Severe bleeding in a patient with factor XIII deficiency and COVID-19. Haemophilia 2021; 27 (01) e140-e142
  CrossrefPubMedGoogle Scholar
• 37 Pinto Pereira J, Hantson P, Gerard L. et al. Management of COVID-19 coagulopathy in a patient with severe haemophilia A. Acta Haematol 2021; 144 (03) 319-321
  CrossrefPubMedGoogle Scholar
• 38 Anžej Doma S, Lukič M. Severe COVID-19 infection management in a patient with mild haemophilia-a case report. Hematol Rep 2022; 14 (02) 103-107
  CrossrefPubMedGoogle Scholar
• 39 Taranchenko YL, Martinez Garcia F, Benitez-Hidalgo O, Aguilar M, Massons J, Nuñez JH. COVID-19 infection after a total knee arthroplasty in a patient with hemophilia a: a case report. JBJS Case Connect 2020; 10 (03) 00537
  CrossrefPubMedGoogle Scholar
• 40 Cui D, Zhang A, Liu A, Hu Q. Clinical findings in a patient with haemophilia A affected by COVID-19. Haemophilia 2020; 26 (04) e214-e216
  PubMedGoogle Scholar
• 41 Zanon E, Pasca S, Campello E, Spiezia L, Vettor R, Simioni P. How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. J Thromb Thrombolysis 2020; 50 (04) 795-798
  CrossrefPubMedGoogle Scholar
• 42 Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV, Martín Salces M, García-Barcenilla S, Jiménez-Yuste V. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis. J Thromb Haemost 2020; 18 (09) 2202-2204
  CrossrefPubMedGoogle Scholar
• 43 Dorgalaleh A, Dabbagh A, Tabibian S, Bahraini M, Rafieemehr H. Persistent hiccups in a patient with mild congenital factor V deficiency and COVID-19; clinical and laboratory finding of a rare bleeding disorder. Int J Lab Hematol 2021; 43 (02) e87-e88
  CrossrefPubMedGoogle Scholar
• 44 Sattler L, Feugeas O, Hager C, Grunebaum L, Desprez D. COVID-19 in a pediatric patient with Glanzmann thrombasthenia. Pediatr Blood Cancer 2020; 67 (10) e28662
  CrossrefPubMedGoogle Scholar
• 45 Tarawah R, Tarawah A. COVID-19 in von Willebrand disease type 3 child. Haemophilia 2021; 27: 140
  PubMedGoogle Scholar
• 46 Arun S, Cherian TG, Philip C. Multisystem inflammatory syndrome in a neonate with severe hemophilia - a diagnostic challenge in COVID times: a case report. BMC Pediatr 2022; 22 (01) 397
  CrossrefPubMedGoogle Scholar
• 47 Vagrecha A, Stanco J, Majeed S, Kouides P, Acharya SS. Primary thromboprophylaxis in a patient with type 3 von Willebrand disease and severe COVID-19 infection. Haemophilia 2021; 27 (04) e517-e519
  CrossrefPubMedGoogle Scholar
• 48 Urbaniak-Kujda D, Biernat MM, Skalec T, Jacków-Nowicka J, Windyga J, Wróbel T. Successful treatment of COVID-19 in a patient with severe haemophilia A on emicizumab prophylaxis in the intensive care unit. Haemophilia 2021; 27 (04) e567-e570
  CrossrefPubMedGoogle Scholar